FDA cracks down on drug advertising
Food and Drug Administration officials are unhappy about the proliferation of ads for prescription drugs that minimize risk information, hype benefits, make unsupported claims and even fail to acknowledge serious product warnings.
Washington, D.C. - Food and Drug Administration officials are unhappy about the proliferation of ads for prescription drugs that minimize risk information, hype benefits, make unsupported claims and even fail to acknowledge serious product warnings. Tom Abrams , director of FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) says that the "quality of DTC advertising has declined" in recent years and that the overall tone of ads in less serious. Abrams called on marketers to make ads more educational and useful to consumers. Last year, DDMAC sent manufacturers 12 warning letters, compared with four to five in previous years, and Abrams expects this stepped-up compliance level to continue.
- Jill Wechsler
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
